Margetuximab is an Fc-engineered, HER2-targeted monoclonal antibody approved by the U.S. FDA (as margetuximab-cmkb, Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. It binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain, and mediates antibody-dependent cellular cytotoxicity (ADCC).